<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200808048334N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-03-01</date_registration>
      <primary_sponsor>Oroumia University of Medical Sciences</primary_sponsor>
      <public_title>Investigating effect of virtual reality Game Therapy on fear of child birth</public_title>
      <acronym></acronym>
      <scientific_title>Investigating effect of virtual reality Game Therapy on fear of child birth in primiparous women referring to perinatal clinic of Emam Khomeini hospital in Mahabad in 2021</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>130</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/50608</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: The samples will be divided into two groups of intervention and comparison by Blocked Randomization method. In this study, the allocation of two groups of intervention and comparison will be such that all possible modes for placing the letters A and B in the four blocks will be considered, which includes a total of 6 modes. These 6 modes are numbered from 1 to 6 and the required number of 4 blocks will be determined based on the number of samples studied. Then we will line up the required number, a random number based on a table of random numbers in a row: Of course, numbers above 6 will not be considered. Finally, based on the order of the numbers extracted from the table, the blocks related to each number will be listed in order, and when the samples are entered into the study, each person will take a specific letter in the order obtained. For example, according to the order (AABB / ABAB), the 5th person will be in group A.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: Fear of childbirth. Condition 2: Childbirth pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Fear questionnaire and pain intensity measurement scale (research tools) will be completed at the beginning of the active phase of labor (4 cm dilatation) for both groups, then the virtual reality headset will be available to the intervention group after entering the active phase of labor and regular uterine contractions Will be inserted (The virtual reality headset is a 3D glasses that the mother is asked to wear, while wearing glasses, a game begins in three-dimensional space. The game called "Snow World" is designed in such a way that there is a black dot on the scene that we ask the mother to mark that point on the snowmen and earn points with each correct marking. It's just a fun game and can be stopped whenever the mother feels tired.) depending on the participant's wishes, but the minimum time to use the headset will be 20 minutes until the end of the first stage of labor (10 cm dilation) By entering the active phase of labor, pain and fear of childbirth in several stages, during the first stage, labor will be evaluated in dilatations of 4-6-8-10 cm. Intervention 2: Control group: Routine delivery care for mothers and infants in the control group will be performed in accordance with the hospital routine.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The research team will decide on the publication of participants' data after the end of the study</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Halime Mohammadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 6, West imam khomeini hospital., Mahabad town</address>
        <city>Mahabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5913754841</zip>
        <telephone>+98 44 4222 6155</telephone>
        <email>mid.asrin.m@gmail.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Elham Ebrahimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Nosrat st. Tohid sq. Tehran I.IRAN</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>141973317</zip>
        <telephone>+98 21 6691 4368</telephone>
        <email>Ebrahimi_308@yahoo.com</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Primiparous women
Gestational age 37 weeks and older
single pregnancy
Women 18 to 45 years old</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>45 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Primiparous women with twin pregnancies and more
Illiterate women
Women with vision or hearing problems
Women with chronic diseases
History of mental illness</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F40.232</hc_code>
      <hc_code>G89.18</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Fear of other medical care</hc_keyword>
      <hc_keyword>Other acute postprocedural pain</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Fear questionnaire and pain intensity measurement scale (research tools) will be completed at the beginning of the active phase of labor (4 cm dilatation) for both groups, then the virtual reality headset will be available to the intervention group after entering the active phase of labor and regular uterine contractions Will be inserted (The virtual reality headset is a 3D glasses that the mother is asked to wear, while wearing glasses, a game begins in three-dimensional space. The game called "Snow World" is designed in such a way that there is a black dot on the scene that we ask the mother to mark that point on the snowmen and earn points with each correct marking. It's just a fun game and can be stopped whenever the mother feels tired.) depending on the participant's wishes, but the minimum time to use the headset will be 20 minutes until the end of the first stage of labor (10 cm dilation) By entering the active phase of labor, pain and fear of childbirth in several stages, during the first stage, labor will be evaluated in dilatations of 4-6-8-10 cm.</i_keyword>
      <i_keyword>Control group: Routine delivery care for mothers and infants in the control group will be performed in accordance with the hospital routine</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fear of childbirth. Timepoint: The fear of childbirth questionnaire will be evaluated at the beginning of the active phase of labor (dilation of 4 cm) and by entering the active phase in several stages, during the first phase of labor in dilatations of 4-6-8-10 cm. Method of measurement: Childbirth Attitude Questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Childbirth pain. Timepoint: Childbirth pain questionnaire at the beginning of the active phase of labor (dilatation 4 cm) and entering the active phase in several stages, during the first phase of labor in dilatations of 4-6-8-10 cm will be evaluated. Method of measurement: The visual scale for measuring pain intensity is a 10 cm ruler with the word painless written on the left end and the most severe pain on the right end.</sec_outcome>
      <sec_outcome>Childbirth Self‐Efficacy. Timepoint: Childbirth Self‐Efficacy Inventory at the beginning of the active phase of labor (dilatation 4 cm) and entering the active phase in several stages, during the first phase of labor in dilatations of 4-6-8-10 cm will be evaluated. Method of measurement: Childbirth Self‐Efficacy Inventory.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Oroumia University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-12-22</approval_date>
        <contact_name>Ethic commitee of Tehran University of Medical Sciences</contact_name>
        <contact_address>University of Nursing and Midwifery and Faculty of Rehabilitation - Tehran University of Medical Sciences Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
